On June 12, China Grand Pharmaceutical rose 3.14% in regular trading, trading at HK$4.61/share, with turnover of HK$110 million. The stock rebounded after consecutive declines of 3.22% and 3.08% on June 8 and June 10 respectively.

On the news front, the company's pipeline data presented at the ASCO annual meeting showed positive results. Its bemosubamab combined with platinum-based chemotherapy followed by anlotinib in first-line NSCLC demonstrated a median PFS of 14.42 months versus 8.34 months (HR=0.67), with PD-L1-negative patients also benefiting (mPFS 12.45 vs. 6.54 months, HR=0.61). Additionally, the broader pharmaceutical sector showed signs of recovery, with Hengrui Pharma up 2.38%, Simcere Pharma up 2.37%, and CSPC Pharma up 1.11%, suggesting easing of the systematic selling pressure that had weighed on the sector in prior sessions.

The company also recently completed the cancellation of 40.35 million repurchased shares and launched its global R&D headquarters in Shanghai with an investment of RMB 1.8 billion, signaling continued commitment to innovation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)